$34.60 -$1.16 (-3.2%)

11:14 AM EDT on 05/22/19

Albireo Pharma Inc (NASDAQ:ALBO)

CAPS Rating: 2 out of 5

A specialty pharmaceutical company, which focused on the development and commercialization of innovative treatments for endocrine disorders such as diabetes and osteoporosis.

Current Price $34.60 Mkt Cap $383.6M
Open $35.76 P/E Ratio 0.00
Prev. Close $35.75 Div. (Yield) $0.00 (0.0%)
Daily Range $34.60 - $35.76 Volume 4,362
52-Wk Range $21.90 - $38.48 Avg. Daily Vol.

Caps

How do you think NASDAQ:ALBO will perform against the market?

Add Stock to CAPS Watchlist

All Players

136 Outperform
17 Underperform
 

All-Star Players

19 Outperform
5 Underperform
 

Wall Street

6 Outperform
1 Underperform
 

Top NASDAQ:ALBO Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

bargain123 (39.77)
Submitted November 26, 2013

it's kind of a interesting space,I believe, they are doing a hot research at the right time, when the world is getting overpopulated with diabetics and obese people, This is one of my ultra cheap speculative plays that is really hard to ignore.

line70day (< 20)
Submitted December 16, 2013

Involved in reverse split must work under new Co. rules needs FDA & NDA approval Top line results from its phase 1 clincal trial of two insulins analig-based formulations 228 & 250 in trial both meet Co. expections .Co. has not made any money

NASDAQ:ALBO VS S&P 500 (SPY)

Fools bullish on NASDAQ:ALBO are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about ALBO.

Recs

0
Member Avatar elvisbeatlesfan (30.63) Submitted: 7/11/2014 12:54:27 PM : Outperform Start Price: $53.10 NASDAQ:ALBO Score: -75.71

Believe we are near the bottom at this price

Recs

1
Member Avatar line70day (< 20) Submitted: 12/16/2013 1:54:31 PM : Underperform Start Price: $65.70 NASDAQ:ALBO Score: +105.55

Involved in reverse split must work under new Co. rules needs FDA & NDA approval Top line results from its phase 1 clincal trial of two insulins analig-based formulations 228 & 250 in trial both meet Co. expections .Co. has not made any money

Recs

1
Member Avatar bargain123 (39.77) Submitted: 11/25/2013 7:38:00 PM : Outperform Start Price: $67.80 NASDAQ:ALBO Score: -106.03

it's kind of a interesting space,I believe, they are doing a hot research at the right time, when the world is getting overpopulated with diabetics and obese people, This is one of my ultra cheap speculative plays that is really hard to ignore.

Leaderboard

Find the members with the highest scoring picks in ALBO.

Score Leader

seanchile

seanchile (83.59) Score: +349.89

The Score Leader is the player with the highest score across all their picks in ALBO.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
seanchile 83.59 2/12/2009 Underperform 3Y $606.00 -94.16% +255.73% +349.89 0 Comment
anticitradeshort 35.42 4/20/2009 Underperform NS $658.80 -94.63% +237.76% +332.39 0 Comment
tcss007 26.12 1/11/2010 Underperform 5Y $583.20 -93.93% +148.47% +242.40 0 Comment
copydog1981 < 20 10/8/2010 Underperform 3W $542.40 -93.48% +146.39% +239.87 2 Comments
BeatIBD 51.91 9/15/2008 Underperform 3M $670.80 -94.72% +142.21% +236.93 0 Comment
pdt24 < 20 9/9/2008 Underperform 5Y $721.20 -95.09% +132.15% +227.24 0 Comment
ahknaten74 94.59 3/24/2008 Underperform NS $1,273.20 -97.22% +122.43% +219.66 0 Comment
ToePic < 20 2/25/2008 Underperform NS $1,627.20 -97.83% +119.87% +217.69 0 Comment
dbirder 70.88 4/21/2008 Underperform 1Y $1,538.40 -97.70% +114.40% +212.10 0 Comment
shortcream 98.87 1/25/2011 Underperform 5Y $268.68 -86.83% +122.52% +209.35 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
trackglobalhunte < 20 5/26/2011 Outperform NS $248.40 -85.75% +116.57% -202.33 0 Comment
TrackSwensen < 20 12/31/2009 Outperform 1Y $520.80 -57.83% +14.59% -72.42 12/31/2010 @ $219.60 0 Comment
TrackWedbush 88.10 3/25/2009 Outperform NS $585.60 -93.96% +253.16% -347.12 0 Comment
TrackArgus 83.21 9/19/2008 Underperform NS $621.60 -94.31% +130.54% +224.85 0 Comment
TrackLadenburg < 20 9/8/2008 Outperform NS $663.60 -63.83% -5.13% -58.70 11/2/2010 @ $240.00 0 Comment
TrackLeerinkSwan 97.47 8/25/2008 Outperform NS $2,076.00 -98.30% +129.07% -227.37 0 Comment
TrackCantorFitz 34.21 5/16/2008 Outperform NS $1,995.60 -98.23% +107.68% -205.90 0 Comment
TrackBBTCapMkts 65.18 5/16/2008 Outperform NS $1,995.60 -98.23% +107.68% -205.90 0 Comment
TrackPacificGrow < 20 5/2/2008 Outperform NS $1,708.80 -95.79% -2.24% -93.56 4/17/2012 @ $71.88 0 Comment
TrackJPMorgan 84.65 2/27/2008 Outperform NS $1,678.80 -67.83% -13.63% -54.20 4/30/2010 @ $540.00 0 Comment
TrackPZK < 20 2/25/2008 Outperform NS $1,702.80 -95.78% +1.43% -97.21 4/17/2012 @ $71.88 0 Comment
TrackBofASec 91.46 6/20/2007 Outperform NS $2,626.80 -98.65% +95.83% -194.48 0 Comment

Advertisement